The Finnish trial of prostate cancer screening: where are we now?

Finne, P; Stenman, U H; Määttänen, L; Mäkinen, T; Tammela, T L J; Martikainen, P; Ruutu, M; Ala-Opas, M; Aro, J; Karhunen, P J; Lahtela, J; Rissanen, P; Juusela, H; Hakama, M; Auvinen, A

Finne, P; Stenman, U H; Määttänen, L; Mäkinen, T; Tammela, T L J; Martikainen, P; Ruutu, M; Ala-Opas, M; Aro, J; Karhunen, P J; Lahtela, J; Rissanen, P; Juusela, H; Hakama, M; Auvinen, A.

Affiliation

Finne P; Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. patrik.finne@hus.fi

BJU Int ; 92 Suppl 2: 22-6, 2003 Dec.

Article in En | MEDLINE | ID: mdl-14983949

Subject(s)

Mass Screening/methods; Prostate-Specific Antigen/blood; Prostate/pathology; Prostatic Neoplasms/diagnosis; Aged; Biopsy/methods; Cost-Benefit Analysis; Finland/epidemiology; Humans; Male; Middle Aged; Pedigree; Prognosis; Prostatic Neoplasms/blood; Prostatic Neoplasms/mortality; Quality of Life

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostate / Prostatic Neoplasms / Mass Screening / Prostate-Specific Antigen Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Screening_studies Aspects: Patient_preference Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: BJU Int Journal subject: UROLOGIA Year: 2003 Document type: Article Affiliation country: Finland

Search on Google

Add to My VHL

XML

PubMed Links